Data / Drug companies / Hematopoietic Stem Cell Mobilizer
Hematopoietic Stem Cell Mobilizer drugs: 1 drug from 13 companies in the FDA NDC directory
Hematopoietic Stem Cell Mobilizer is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 13 products in this class from 13 companies, covering 1 drug by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on June 16, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 13Companies
- 13Products
- 1Drugs by generic name
Drugs in the Hematopoietic Stem Cell Mobilizer class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Plerixafor | 13 | 13 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Amneal Pharmaceuticals LLC | 1 | injection, solution | Generic drugs (ANDA) | July 25, 2023 |
| Bryant Ranch Prepack | 1 | injection, solution | Generic drugs (ANDA) | July 25, 2023 |
| Camber Pharmaceuticals, Inc. | 1 | injection, solution | Generic drugs (ANDA) | June 16, 2025 |
| Dr. Reddy's Laboratories Inc. | 1 | solution | Generic drugs (ANDA) | November 6, 2023 |
| Eugia US LLC | 1 | solution | Generic drugs (ANDA) | July 24, 2023 |
| Fresenius Kabi USA, LLC | 1 | injection, solution | Authorized generics (NDA) | June 22, 2023 |
| Gland Pharma Limited | 1 | injection, solution | Generic drugs (ANDA) | May 3, 2024 |
| Meitheal Pharmaceuticals Inc. | 1 | solution | Generic drugs (ANDA) | July 24, 2023 |
| Novadoz Pharmaceuticals LLC | 1 | injection, solution | Generic drugs (ANDA) | July 25, 2023 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | August 1, 2024 |
| Sanofi-Aventis U.S. LLC | 1 | injection, solution | New drug applications (NDA) | September 1, 2013 |
| Zydus Lifesciences Limited | 1 | injection | Generic drugs (ANDA) | July 28, 2023 |
| Zydus Pharmaceuticals USA Inc. | 1 | injection | Generic drugs (ANDA) | July 28, 2023 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 8 | 61.5% |
| Solution | 3 | 23.1% |
| Injection | 2 | 15.4% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.